Alternative immune cells may surpass T cells to fight solid tumors
Penn researchers have shown success using genetically engineered macrophages, an immune cell that eats invaders in the body, to target solid tumors.
A new way to predict lung cancer treatment response: The blood test
A Penn study shows a better clinical response to immunotherapy correlates with higher ratio of tumor mutations detected by a liquid biopsy.
CRISPR-edited immune cells can survive and thrive after infusion into cancer patients
In the first U.S. clinical trial, cells removed from patients and brought back into the lab were able to kill cancer months after their original manufacturing and infusion.
Defect driving resistance to CAR T therapy identified
A new study identifies the mechanism that prevents cell death, and can guide future immunotherapy strategies in patients whose blood cancers are resistant to CAR T therapy.
Penn nanoparticles are less toxic to T cells engineered for cancer immunotherapy
By using messenger RNA across the T cell’s membrane via a nanoparticle instead of a DNA-rewriting virus on extracted T cells, CAR T treatments could have fewer side effects.
These overlooked global diseases take a turn under the microscope
Faculty at the School of Veterinary Medicine target neglected tropical diseases with advanced science, cross-disciplinary collaborations, and work in the lab and the field.
Positive results in first-in-U.S. trial of CRISPR-edited immune cells
Genetically editing a cancer patient’s immune cells using CRISPR/Cas9 technology, then infusing those cells back into the patient appears safe and feasible based on early data from the first-ever clinical trial to test the approach in humans in the United States.
To monitor cancer therapy, researchers tag CAR T cells with imaging markers
With CAR T cell therapy, a patient’s own immune cells are genetically modified and inserted back into the body to find and kill cancer. Now scientists have now discovered a new way to track CAR T cells in the body.
Researchers unravel the early makings of an exhausted T cell
Knowing which T cells will lose the battle against cancer earlier could inform treatments and the development of new immunotherapies.
Algorithm personalizes which cancer mutations are best targets for immunotherapy
A new model developed by researchers in the Abramson Cancer Center hand-picks cancer cells to target for more effective, customized cancer vaccines.